MP63-05 A RANDOMIZED CONTROLLED TRIAL COMPARING TELEMEDICINE VERSUS IN-PERSON OFFICE VISITS FOR THE FOLLOW-UP OF OVERACTIVE BLADDER

Abstract

You have accessJournal of UrologyUrodynamics/Lower Urinary Tract Dysfunction/Female Pelvic Medicine: Non-neurogenic Voiding Dysfunction II (MP63)1 Sep 2021MP63-05 A RANDOMIZED CONTROLLED TRIAL COMPARING TELEMEDICINE VERSUS IN-PERSON OFFICE VISITS FOR THE FOLLOW-UP OF OVERACTIVE BLADDER Spencer Mossack, Igor Inoyatov, Chris Du, Phillip Fonseca, Edwin Lee, Heng Ruan, and Jason Kim Spencer MossackSpencer Mossack More articles by this author , Igor InoyatovIgor Inoyatov More articles by this author , Chris DuChris Du More articles by this author , Phillip FonsecaPhillip Fonseca More articles by this author , Edwin LeeEdwin Lee More articles by this author , Heng RuanHeng Ruan More articles by this author , and Jason KimJason Kim More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002103.05AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Telemedicine has been increasingly utilized in the management of urologic patients since the start of the global COVID-19 pandemic. Overactive bladder (OAB) is a condition that may ideally suited for the use of telemedicine as initial treatment options are behavioral modification and pharmacotherapy. We sought to evaluate if there was an overall difference in patient follow up rates between telemedicine visits and in-person visits. METHODS: New patients presenting to our clinic with OAB from 7/2020 to 2/2021 were randomized into 2 follow-up groups, telemedicine and in-person visits. After each visit, patients were prompted to complete a survey regarding their visit experience. A prospective database was maintained to compare follow-up rates, satisfaction rates, and time commitment in each group. RESULTS: A total of 46 patients were randomized, 24 to the telemedicine group and 22 to the in-person group. There were no significant differences in baseline demographics, Urogenital Distress Inventory-6/Incontinence Impact Questionnaire-7 scores, or history of telemedicine experience. There was no significant difference in follow-up rates between the telemedicine and in-person follow-up groups at 30-days (33% vs. 27%, p=0.66), or 60-days (63% vs. 50% p=0.39). Satisfaction rates were extremely high and there was no significant difference between the groups. There was a significant difference between the average telemedicine visit time and in-person visit time (10.88 mins vs. 21.84 mins, p=0.004). For in-person visits, the average travel time was 48 minutes (range 10-90 mins) and average miles traveled was 21 miles (range 5-35 miles). Patients in the telemedicine group reported technical difficulties in 12% of follow-up appointments (N=2). CONCLUSIONS: There was no significant difference in follow-up or satisfaction rates between telemedicine and in-person visits. In-person visits took half the length of time compared to in-person visits. On average patients in the telemedicine group saved approximately 1 hour per follow-up visit. Telemedicine visits save both the provider and patient significant amounts of time without sacrificing patient satisfaction and follow-up rates. Source of Funding: NA © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e1103-e1103 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Spencer Mossack More articles by this author Igor Inoyatov More articles by this author Chris Du More articles by this author Phillip Fonseca More articles by this author Edwin Lee More articles by this author Heng Ruan More articles by this author Jason Kim More articles by this author Expand All Advertisement Loading ...